Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1855 results
December 2019
-
Press release
Novartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platforms
With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM-3 immunotherapy, with decitabine on preliminary response rates in… -
Featured News
Behind the research driving our data at medical conferences
Novartis data at 2019 ASH and SABCS underscore our evolving R&D approach in innovative platforms to reimagine medicine and help improve patient outcomes.
November 2019
-
Featured News
Novartis opens facility for innovative cell and gene therapies in Switzerland
-
Ad hoc release
Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL… -
Press release
Novartis launches Innovation Prize for Assistive Tech to encourage new technologies that address unmet needs of the multiple sclerosis community
The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) identifies and embraces technology that aims to improve mobility and daily life for people living with MS Applications are… -
Press release
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated… -
Ad hoc release
New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.… -
Press release
Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
If approved, Mayzent® (siponimod) will be the first and only oral treatment specifically indicated for patients with active secondary progressive multiple sclerosis (SPMS) in Europe[1]) CHMP… -
Press release
Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa
The strategy is aligned with the Novartis Access Principles, which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally A… -
Story Patient Perspectives
Visionary: Silke Mader has a vision for the care of premature infants and their parents
Caring for a baby with retinopathy of prematurity (ROP) has never been easy. But mother and social visionary Silke Mader has made it her life’s work to ensure that parents dealing with ROP and other complications today get more support than she did.
-
Press release
Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment
Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when… -
Press release
New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis
42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1] PREVENT is…